SLC2A6

SLC2A6 (GLUT6) is a facilitative glucose transporter family member that functions less as a bulk glucose importer than as a context-dependent regulator of glycolytic and immune programs across multiple tissues (PMID:29664675, PMID:27825869). Genetic ablation in mice produces no defect in development, growth, or whole-body glucose metabolism, and siRNA knockdown in endothelial cells fails to reduce deoxy-glucose uptake, establishing that GLUT6 is dispensable for basal glucose transport and systemic glucose homeostasis (PMID:29664675, PMID:27825869). Its expression is induced by NF-κB signaling: constitutively active RELA and TNFα stimulation specifically upregulate SLC2A6 among glucose transporters, while dominant-negative RELA suppresses it (PMID:32512041). Functionally, SLC2A6 supports myoblast differentiation through a glycolytic LDHB-dependent axis controlling lactate accumulation (PMID:35850889), and restrains glucose-stimulated insulin secretion from pancreatic islets in the obese (ob/ob) state (PMID:36077188). In innate immunity, Kupffer-cell SLC2A6 compromises host defense against Streptococcus pneumoniae by downregulating anti-phosphorylcholine natural antibodies, thereby limiting classical-pathway complement activation and bacterial opsonization (PMID:41904952). Beyond these roles, the molecular mechanism by which SLC2A6 couples to these downstream pathways—and whether it acts as a transporter in each context—has not been resolved in the available corpus.

1. 2016 Medium

   Testing whether GLUT6 contributes to cellular glucose uptake addressed the basic assumption that this transporter family member moves glucose; the result reframed SLC2A6 as functionally distinct from canonical glucose transporters.

   Evidence siRNA knockdown of SLC2A6 versus GLUT1/GLUT3 with 14C-deoxy-glucose uptake assay in HUVEC

   PMID:27825869

   Open questions at the time

   • A negative uptake result does not establish what SLC2A6 does transport, if anything
   • Limited to endothelial cells under basal conditions
2. 2018 High

   A clean knockout tested whether GLUT6 is required for organismal glucose physiology; its dispensability established that GLUT6 is not a major systemic metabolic regulator and redirected attention to tissue-specific roles.

   Evidence CRISPR-Cas9 Slc2a6 knockout mice with glucose tolerance, insulin, and body composition phenotyping under chow and Western diet

   PMID:29664675

   Open questions at the time

   • Does not exclude tissue-restricted or condition-specific functions
   • Sex-specific minor effects (female fat accumulation, RER) left unexplained mechanistically
3. 2020 Medium

   Identifying RELA as a direct upstream activator answered how SLC2A6 expression is controlled, linking it specifically to NF-κB/inflammatory signaling rather than general metabolic regulation.

   Evidence Constitutively active and dominant-negative RELA overexpression plus TNFα stimulation with Western blot and RT-qPCR in endometrial cells

   PMID:32512041

   Open questions at the time

   • Direct promoter binding/occupancy not demonstrated
   • Functional consequence of NF-κB-driven SLC2A6 induction not tested in this system
4. 2022 Medium

   Knockdown in myoblasts connected SLC2A6 to a differentiation program, showing it acts through glycolysis via LDHB rather than as a passive transporter.

   Evidence RNAi knockdown with paired transcriptomics and metabolomics and differentiation/myotube readouts in C2C12 cells

   PMID:35850889

   Open questions at the time

   • Mechanistic link between SLC2A6 and LDHB regulation not defined
   • Whether transport activity is required for the differentiation phenotype unknown
5. 2022 Medium

   Crossing the knockout onto an obese background revealed a conditional role: GLUT6 restrains islet insulin secretion specifically under obesity, exposing a function invisible in lean animals.

   Evidence Slc2a6 knockout x ob/ob mice with ex vivo glucose-stimulated insulin secretion assay

   PMID:36077188

   Open questions at the time

   • Cell-autonomous beta-cell mechanism not established
   • Single functional readout in one genetic background
6. 2024 Low

   Overexpression in breast cancer cells tied SLC2A6 to proliferation control and a candidate protein partner, suggesting a non-transport, interaction-based mode of action.

   Evidence SLC2A6 overexpression with RNA-seq, protein profiling identifying HSPA6, and proliferation/apoptosis assays

   PMID:38622369

   Open questions at the time

   • HSPA6 interaction not confirmed by reciprocal Co-IP or pulldown
   • Overexpression phenotype may not reflect endogenous function
   • Direction of effect (tumor-suppressive) conflicts with HCC findings
7. 2025 Low

   Loss-of-function in hepatocellular carcinoma cells linked SLC2A6 to tumor aggressiveness through ferroptosis, indicating a pro-proliferative role in this cancer context.

   Evidence SLC2A6 knockdown/knockout with proliferation/migration/invasion assays, xenografts, and GO/KEGG enrichment

   PMID:39833197

   Open questions at the time

   • Ferroptosis link rests on enrichment analysis, not direct mechanistic reconstitution
   • No molecular pathway connecting SLC2A6 to ferroptosis effectors
8. 2026 Medium

   Kupffer-cell loss-of-function defined a concrete innate-immune mechanism, showing SLC2A6 suppresses natural antibodies and complement-mediated bacterial clearance.

   Evidence Slc2a6 genetic loss-of-function in Kupffer cells with in vivo bacteremia, serum natural antibody quantification, and complement activation assays

   PMID:41904952

   Open questions at the time

   • Molecular link between SLC2A6 activity and natural-antibody levels unresolved
   • Whether transport function underlies the immune phenotype unknown

• The core biochemical activity of SLC2A6—its physiological substrate and how transport (or a non-transport function) couples to NF-κB induction, glycolytic LDHB control, insulin secretion, and immune regulation—remains unresolved.
• No defined transported substrate
• No structural model
• Mechanistic unification across metabolic, cancer, and immune roles absent